Characteristics of CD5-Positive Splenic Marginal Zone Lymphoma with Leukemic Manifestation ; Clinical, Flow Cytometry, and Histopathological Findings of 11 Cases

• Kojima Minoru

  Department of Hematology and Oncology, Tokai University School of Medicine

• Sato Eriko

  Department of Hematology, Juntendo University School of Medicine

• Oshimi Kazuo

  Department of Hematology, Juntendo University School of Medicine

• Murase Takuhei

  Department of Internal Medicine, Nishio Municipal Hospital

• Koike Tadashi

  Nagaoka Red Cross Hospital

• Tsunoda Sinichirou

  Sakae Kyousai Hospital

• Matsumoto Toshiharu

  Department of Pathology, Juntendo University School of Medicine

• Marutsuka Kousuke

  Pathology Division, Miyazaki Medical College Hospital, University of Miyazaki

• Ogiya Daisuke

  Department of Hematology and Oncology, Tokai University School of Medicine

• Moriuchi Makiko

  Department of Hematology and Oncology, Tokai University School of Medicine

• Tokunaka Mami

  Department of Pathology, Tokai University School of Medicine

• Yara Kikuti Yukie

  Department of Pathology, Tokai University School of Medicine

• Kikuchi Tomoki

  Department of Pathology, Tokai University School of Medicine

• Nakamura Naoya

  Department of Pathology, Tokai University School of Medicine

• Ando Kiyoshi

  Department of Hematology and Oncology, Tokai University School of Medicine

抄録

Splenic marginal zone lymphoma (SP-MZL) is a rare low-grade B-cell neoplasm that often shows leukemic manifestation. Less than 20% of cases of SP-MZL express CD5. We analyzed 11 cases of CD5-positive SP-MZL with leukemic manifestation. The clinical characteristics of these cases did not differ from those of CD5-negative SP-MZL. Flow cytometry revealed positive results as follows : CD3, 0/9 ; CD5, 11/11 ; CD10, 0/11 ; CD11c, 4/10, CD13, 5/11 ; CD19, 11/11 ; CD20, 10/11 ; CD21, 4/4 ; CD22, 7/7 ; CD23, 5/10 ; CD25, 8/11 ; FMC7, 5/7 ; κ type 6/9, and λ type 2/9. All 3 cases with monoclonal γ-globulinemia expressed CD13. Resected spleen exhibited a proliferation of neoplastic cells in white pulp in all 8 splenectomy patients and a marginal pattern was detected in 5 patients. Only 2 cases showed involvement of red pulp. Immunohistochemistry showed that the lymphoma cells were positive for CD5, CD20, and BCL-2 and negative for CD3, CD10, cyclin D1, BCL-6, and MUM-1 in all 11 cases. These results suggest that CD5-positive SP-MZL differs from B-cell chronic lymphocytic leukemia, that CD13 expression is found in about half of CD5-positive SP-MZL cases, and that CD5-positive SP-MZL may be related to memory B-cell neoplasm or plasma cell differentiation.

収録刊行物

• Ｊｏｕｒｎａｌ　ｏｆ　Ｃｌｉｎｉｃａｌ　ａｎｄ　Ｅｘｐｅｒｉｍｅｎｔａｌ　Ｈｅｍａｔｏｐａｔｈｏｌｏｇｙ

  Ｊｏｕｒｎａｌ　ｏｆ　Ｃｌｉｎｉｃａｌ　ａｎｄ　Ｅｘｐｅｒｉｍｅｎｔａｌ　Ｈｅｍａｔｏｐａｔｈｏｌｏｇｙ 50 (2), 107-112, 2010

  日本リンパ網内系学会

キーワード

• splenic marginal zone lymphoma
• CD5
• CD13
• immunohistochemistry

詳細情報

• CRID: 1390001204703535232
• NII論文ID: 10027647902
• NII書誌ID: AA11556796
• DOI: 10.3960/jslrt.50.107
• ISSN: 18809952
• ISSN: 13464280
• Web Site: https://search.jamas.or.jp/link/ui/2011254625
• 本文言語コード: en
• データソース種別:
  • JaLC
  • Crossref
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可